Discovering, Developing & Commercializing Targeted
Small Molecule Drugs in Cancer

A Year of
Significant
Progress

Read Ron Squarer's
letter to shareholders

Binimetinib

Learn more
about our Phase 3
cancer trials

Filanesib

Learn more about
our multiple
myeloma program